Posts by Ryan Worthen

Ryan is a Senior Research Analyst at PharmSource. He holds a BS degree in biology, with a minor in chemistry and a BA degree in Spanish, from the University of North Carolina at Chapel Hill. Prior to joining PharmSource, Ryan worked as a Research Technician in the Neuroscience Center of the UNC Chapel Hill School of Medicine, and has been a named author on research publications.

Follow the Money: Seres Therapeutics, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Seres Therapeutics, Inc. is a U.S. public pharmaceutical company that discovers and develops drugs to treat infectious, metabolic and inflammatory diseases. As reported in the July 2, 2015 […]

Learn more

Follow the Money: Fate Therapeutics, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Fate Therapeutics, Inc. is a U.S. public pharmaceutical company that develops therapeutics based on modulating cell fate. As reported in the May 28, 2015 issue of the PharmSource […]

Learn more

Follow the Money: Viking Therapeutics, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Viking Therapeutics, Inc. is a U.S. public pharmaceutical company that develops therapies for metabolic and endocrine disorders. As reported in the May 7, 2015 issue of the PharmSource […]

Learn more

New Trend Report Graphing Feature

We’ve created an all-new graphing feature as part of the PharmSource Lead Sheet subscription. You can now graph drug lead data taken from the Lead Sheet to identify and visualize trends and gauge market size during a specified time frame. Selection options for this feature include development phase, API, dosage form, therapeutic area, HQ territory […]

Learn more

Follow the Money: Intercept Pharmaceuticals, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Intercept Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops small molecule drugs for the treatment of chronic liver and metabolic diseases. As reported in the April […]

Learn more

Follow the Money: Inotek Pharmaceuticals

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Inotek Pharmaceuticals is a U.S. public pharmaceutical company that develops therapies with novel mechanisms of action to address significant diseases of the eye. As reported in the February […]

Learn more

Follow the Money: TRACON Pharmaceuticals, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. TRACON Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops novel targeted therapeutics for cancer, age-related macular degeneration, and fibrotic diseases. As reported in the February 5, […]

Learn more

Follow the Money: Agios Pharmaceuticals, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Agios Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops drugs that target metabolic pathways critical to cancer cell growth, proliferation and survival. As reported in the […]

Learn more

Follow the Money: Lexicon Pharmaceuticals, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Lexicon Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops treatments using a gene knockout technology to identify human gene targets in metabolism, cardiology, immunology, gastroenterology, and […]

Learn more

Follow the Money: Chimerix, Inc.

Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities. Chimerix, Inc. is a U.S. public pharmaceutical company that develops orally available antiviral medicines. As reported in the November 6, 2014 issue of the PharmSource Lead Sheet, Chimerix […]

Learn more